AlphAIAlphAI — Financial news for AI agents
quiverquant.comOCT 292 min read$BHC

Bausch Health Companies (BHC) Stock Rises on Q3 2026 Earnings

Bausch Health Companies (BHC) reported Q3 2026 revenue of $2.9B, up 52.75% YoY, with net income of $436M and EPS of $1.17. Cash from operations doubled to $814M, and shares rose 13.73% post-earnings. Insiders sold shares, while institutional investors had mixed activity.

Original reporting
quiverquant.com
Published Oct 29, 2026, 1:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bausch Health Companies (BHC) Stock Rises on Q3 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$BHCBullishHigh
01

Why it matters

The earnings beat and strong cash flow drove a notable post‑market price jump, suggesting short‑term buying interest.

02

Market read

Earnings surprise creates immediate trading opportunity; sector peers may be impacted.

03

What to watch

High debt level ($25.8B) could limit long‑term upside despite earnings beat.

Relevance 8/10Novelty 9/10Timing: after-hours reaction

Background

Bausch Health Companies Inc. (BHC) released its Q3 2026 earnings, showing significant revenue and profit growth.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Bausch Health reported Q3 2026 revenue of $2.9B and EPS $1.17, driving a 13.73% share rise after hours.

Expected impact

potential upward pressure as traders price in the earnings beat

Evidence & confidence

Revenue and profit surged >50% YoY, EPS beat expectations, and the stock already jumped 13.7%.

Market effects

Sector

Improves outlook for the broader pharma/healthcare sector with strong earnings momentum.

Regional

Positive for North American healthcare stocks.

Global

Limited to sector; no broad macro impact.

Counterpoint

What could challenge this read

The earnings surge may be unsustainable if growth slows; watch for guidance on future quarters.

Key entities

  • company
    Bausch Health Companies Inc.

    Issuer of the earnings report.

Read at source← All news

StoryBausch Health posts strong Q3 2026 results, raises full‑year outlook and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 29
$BHCMedAI 8/10

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health (BHC) reported Q3 revenue growth in international and Solta Medical segments, with Solta seeing 18% reported growth. The company reduced net debt by $521M in Q3 and announced a $50M share repurchase program. BHC updated its 2026 outlook, expecting 8% revenue growth and 13% adjusted EBITDA growth. Management remains focused on portfolio performance and operational improvements.

finance.yahoo.com2 min
OCT 28
$BHCHighAI 8/10

[Bausch Health Companies Q3 2026 Earnings Call] Bausch Health Raises Guidance Again as Quarterly Adjusted EBITDA Tops $1 Billion for First Time; Warns of $400–$500 Million XIFAXAN Headwind in 2027

Bausch Health (BHC) reported Q3 2026 revenue of $2.94B, up 10% YoY, with adjusted EBITDA surpassing $1B for the first time. The company raised full-year guidance but warned of $400M-$500M XIFAXAN headwind in 2027 due to Medicare rebates. Salix segment grew 16%, driven by XIFAXAN. Net debt reduced by $1B YTD, with plans for debt redemptions and share repurchases.

finance.biggo.com3 min
OCT 28
$BHCHighAI 8/10

Bausch Health Q3FY26 Results: Adjusted EBITDA up 32% to $1.3 billion

Bausch Health reported a 32% YoY increase in adjusted EBITDA to $1.305 billion for Q3FY26, exceeding $1 billion for the first time. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and cash flow, citing strong performance. Net debt was reduced by $521 million during the quarter. Salix segment drove growth with a 16% revenue increase, while Solta Medical saw reported revenue grow 18% but organic revenue decline 4%.

scanx.trade3 min